海思科：自主研发的创新药HSK47977片IND申请获受理

Core Viewpoint - The company, Haikang, has received acceptance for its IND application for the innovative drug HSK47977, which is a new oral small molecule anti-tumor drug aimed at treating lymphoma [1] Group 1 - The drug HSK47977 is developed independently by the company and is positioned as a global new oral small molecule anti-tumor medication [1] - Currently, there are no clinical data published for drugs targeting the same pathway globally, and there are no similar drugs in clinical stages in China [1]